Morquio Syndrome Treatment Market Size, Share, Growth Analysis, By Treatment(Enzyme Replacement Therapy, Other.), By Disease Type(Morquio A, Morquio B), By Distribution Channel(Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region - Industry Forecast 2025-2032

In addition to recent regulatory approvals, there has been an increase in R&D for the treatment of Morquio syndrome, as shown by the increased inclusion of the condition in the clinical pipelines of the leading market participants. For the Morquio syndrome, for instance, Shire is conducting a Phase 3 Study, Ultragenyx Pharmaceutical Inc. is testing a medicine (AGT 181) in a clinical trial, and ArmaGen, Inc. is also testing a treatment for the syndrome in young patients. The market for treatments for Morquio syndrome is expanding as a result of this as well as increased disease awareness.

Morquio Syndrome Treatment Market Top Player’s Company Profiles

• BioMarin Pharmaceutical Inc.
• Shire (now part of Takeda Pharmaceutical Company Limited)
• Ultragenyx Pharmaceutical Inc.
• Abeona Therapeutics Inc.
• RegenxBio Inc.
• Sangamo Therapeutics Inc.
• REGENXBIO Inc.
• ArmaGen Inc.
• Lysogene S.A.
• Zymenex A/S
• Spark Therapeutics (now part of Roche)
• Orchard Therapeutics plc
• Idorsia Pharmaceuticals Ltd.
• JCR Pharmaceuticals Co., Ltd.
• SOBI (Swedish Orphan Biovitrum AB)
• Green Cross Corporation
• Cabaletta Bio Inc.
• Audentes Therapeutics (now part of Astellas Pharma Inc.)
• Aeglea BioTherapeutics
• Krystal Biotech Inc.

Morquio Syndrome Treatment Market Recent Development

• In February 2021, to provide bottom hole assembly tools and services to directional drillers and operators in the Permian basin, SMG Industries, Inc., a Texas-based oilfield service firm, partnered with Christopher Equipment and Rentals, LLC, Texas.
• In May 2021, The FDA gave Sangamo Therapeutics Inc.'s gene therapy candidate (SB-913), which is in their clinical pathway, the rare pediatric condition classification. BASF SE and NRGene (Israel) established a research agreement in October 2019, with NRGene's cloud-based artificial intelligence (AI) technology being integrated into BASF soybean research initiatives.